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  In this issue of Current Opinion in Pulmonary Medicine, we focus on the problem of 
community- acquired lower respiratory tract infections. It is very clear from the discussions in 
this monograph, that clinical and basic research have translated into tangible ways to improve 
outcomes for  our patients. This has spanned the problems of community acquired pneumonia 
(CAP) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD) , and has 
included interventions from survieillance to specific antimicrobial therapies to vaccines for 
prevention. Epidemiologic studies have focused our attention on unexpected complications of 
lung infection, such as acute cardiac disease, and observational and interventional studies have 
suggested ways to improve outcomes, such as  mortality and readmission to the hospital.  
 One of the most revolutionary advances in the field of lung infection is the realization 
that the normal lower respiratory tract is not sterile, and that it is inhabited by a "microbiome" 
of organisms that is more diverse and numerous than ever imagined ( 1 ). WIth the advent of 
new molecular methods, it is very clear that our understanding of the organisms that 
contribute to illness, which has been dependent on standard culture techniques, is incomplete. 
The presence of the RNA of millions of bacteria, from hundreds of species, is a revolutionary 
finding in both healthy and infected patients. We are just begining to understand how the 
microbiome changes in the presence of acute illness, and this understanding  is likely to lead to 
new concepts of disease pathogenesis and new therapeutic approaches.  Dy and Sethi have 
examined the role of the microbiome in AECOPD (2). They discuss the association of loss in 
microbiome diversity with disease severity. They also report changes in the microbiome with 
smoking, COPD severity, acute exacerbation, and therapy with steroids and antibiotics. This is 
an exciting and evolving field, that may change our understanding of lung infections and the 
best way for treating AECOPD.  
 Maeurer and collegues demonstrate how an understanding of host defense mechanisms 
can lead to novel directions for the therapy of antimicrobial resistant bacterial, fungal and viral 
infections, that are not easily treated by currently available agents (3). They nicely outline 
specific cytokine responses to a wide range of pathogens, which could be amenable to future 
interventions. For example, new host-directed therapies could be emerging with agents such as 
alppa-1-antitrypsin, bone marrow-derived stem cells, specially activated T cells, novel kinase 
inhibitors, and pathogen-specific monoclonal antibodies.  
 We have begun to appreciate that CAP has both short-term and long-term mortality, 
and that its impact is as more than just as an acute illness. One factor that may contribute to 
adverse outcomes, both acutely and after pneumonia resolution, is the development of 
ischemic and arrhythmic cardiac disease. Rae and collegues review new information about the 
association of CAP and cardiac complications, reporting that up to one-third of CAP patients 
may experience cardiovascular complications within 30 days of hospital admission (4). These 
complications include acute myocardial infarction, arrhythmias and congestive heart failure. 
Quite surprisingly, the risk may persist for at least 1 year after pneumonia, and maybe for as 
long as 10 years. The mechanisms are being elucidated, but can include direct invasion of the 
myocardium by organisms such as pneumococcus. Based on these findings, strategies to 
prevent CAP , may soon be viewed as cardioprotective interventions.  
 One of the first steps to improving CAP management, is to recognize which patients are 
at risk for infection with multidrug-resistant (MDR) pathogens. Although CAP has traditionally 
been an infection caused by pneumococcus and other easily treated pathogens, the patients 
who are now affected, are increasingly complex, and moving freely between the community, 
healthcare centers , nursing homes and hospitals, and these exposures add to the risk of 
infection with MDR pathogens. Sibilia et al have discussed the challenges associated with 
identifying patients coming from the community who are  at risk for MDR pathogen pneumonia 
(5). They discuss the potential problems with the concept of healthcare associated pneumonia, 
and review risk factors  for infection with MDR pathogens. These risk factors include: prior 
hospitalization, hemodialysis, home wound care, residence in a nursing home, home infusion 
therapy, recent antibiotics, immune suppression, tube feeding, aspiration, poor functional 
status, and prior infection with an MDR pathogen. The current challenge is to develop a method 
to rapidly identify these patients, and Sibilia and collegues review scoring systems that have 
been developed for this purpose. One unresolved challenge is whether we will be able to use 
epidemiologic data to identify risks for specific pathogens such as methicillin-resistant S. aureus 
and P. aeruginosa, or whether the risk factors will just be able to tell us that any of these 
organisms are possible. It is likely that we will need to combine both epidemiologic data and 
rapid molecular diagnostics, to optimize the identification of patients at risk for infection with 
MDR pathogens, but these efforts could lead to improvements in the selection of appropriate 
and focused empiric therapy.  
 The most important pathogen causing CAP is Streptococcus pneumoniae, or 
pneumococcus, and it too is becoming increasingly resistant to commonly used antibiotics such 
as the penicillins and macrolides. Cilloniz and colleagues have reveiwed this problem and 
provided a look at the incidence and clinical impact of drug-resistant pneumococcus (DRSP) (6). 
They have reported the risks factors for DRSP and have shown how its presence may alter the 
clinical presentation of pneumonia. While the implications for therapy are still evolving, it is 
clear that our focus needs to be on using antibiotics in a way that will halt the development of 
even more resistance. In addition, they point out the double-edged sword of using vaccines for 
prevention. The older pneumococcal conjugate vaccines have led to the emergence of virulent 
"replacement strains" , while the newer, more broad conjugate vaccines may have a large and 
beneficial impact on the future incidence  of pneumococcal pneumonia, and resistance.  
 One clear benefit from our enhanced understanding of CAP is the possibility of 
improving outcomes for our patients, a topic which  Bender and Niederman have reviewed (7). 
Strategies to achieve this  include a renewed focus on the site of care decision, recognizing the 
adverse impact of delayed intubation and delayed admission to the ICU. An awareness of the 
cardiac complications of CAP, may mandate a reconsideration of the need for cardiac 
monitoring in selected patients. Severity scoring systems and biomarkers may also help with 
the site of care decision. Therapy choices are also important contributors to outcome, including 
the benefits that can come from the use of adjunctive empiric macrolide therapy for severely ill 
patients, the reduced mortality with the use of anti-toxin therapy for community acquired 
methicillin resistant S. aureus infection, and the potential benefit of adjunctive corticosteroids 
for selected patients with severe CAP. Finally, they point out the importance of managing the 
comorbid illnesses that are common in CAP patients, with the benefits of improving mortality 
and avoiding readmission to the hospital.  
 This issue of Current Opinion in Pulmonary Medicine is an exciting one, and it illustrates 
the current state of knowledge in community acquired respiratory tract infections. Many recent 
observations have led to changes in patient management that are able to benefit our patients 
today. At the same time, novel and exciting developments in the basic biology of host defenses 
and bacterial pathogenesis are pointing to where future advances will emerge. We are deeply 
grateful to the authors of this issue, and hope that their discussions will stimulate further 
advances in the understanding and management of  these challenging infections.   
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